

## Rapid Method Communication

### Preliminary optimisation of simplified sample preparation method to permit direct detection of SARS-CoV-2 within saliva samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP)

\*Emma L. A. Howson<sup>1,2</sup>, \*Stephen P. Kidd<sup>3\*</sup>, Jason Sawyer<sup>4</sup>, Claire Cassar<sup>4</sup>, David Cross<sup>4</sup>, Tom Lewis<sup>4</sup>, Jess Hockey<sup>4</sup>, Samantha Rivers<sup>4</sup>, Saira Cawthraw<sup>4</sup>, Ashley Banyard<sup>4</sup>, Michael Andreou<sup>5</sup>, Nick Morant<sup>1</sup>, Duncan Clark<sup>1</sup>, Charlotte Walsh<sup>1</sup>, Shailen Laxman<sup>5</sup>, Rebecca Houghton<sup>3</sup>, Joanne Slater-Jefferies<sup>6</sup>, Paula Costello<sup>7</sup>, Ian Brown<sup>4</sup>, Nicholas Cortes<sup>3,8</sup>, Keith M. Godfrey<sup>7,9</sup>, \*Veronica L. Fowler<sup>3</sup>

<sup>1</sup>GeneSys Biotech Limited, Camberley, Surrey, UK

<sup>2</sup>The Pirbright Institute, Ash Road, Woking, Surrey, UK

<sup>3</sup>Hampshire Hospitals NHS Foundation Trust, Department of Microbiology, Basingstoke and Winchester, UK

<sup>4</sup>Animal and Plant Health Agency, New Haw, Addlestone, Surrey, UK

<sup>5</sup>OptiSense Limited, Horsham, West Sussex, UK

<sup>6</sup>National Biofilms Innovation Centre, University of Southampton, UK

<sup>7</sup>MRC Lifecourse Epidemiology Unit, University of Southampton, UK

<sup>8</sup>Gibraltar Health Authority, Gibraltar, UK

<sup>9</sup>NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton, UK

\*Corresponding author: E-mail: [stephen.kidd@hhft.nhs.uk](mailto:stephen.kidd@hhft.nhs.uk)

\*Joint first authors

### Running title

RT-LAMP assay for the rapid detection of SARS-CoV-2 in saliva.

### Keywords

SARS-CoV-2, COVID-19, RT-LAMP, rapid diagnostics, near patient testing, direct detection

36 **Abstract**

37 We describe the optimization of a simplified sample preparation method which permits rapid and  
38 direct detection of SARS-CoV-2 RNA within saliva using reverse-transcription loop-mediated  
39 isothermal amplification (RT-LAMP). Treatment of saliva samples prior to RT-LAMP by dilution 1:1 in  
40 Mucolyse™, followed by dilution (within the range of 1:5 to 1:40) in 10% (w/v) Chelex® 100 Resin and  
41 a 98°C heat step for 2 minutes enabled detection of SARS-CoV-2 RNA in all positive saliva samples  
42 tested, with no amplification detected in pooled negative saliva. The time to positivity for which SARS-  
43 CoV-2 RNA was detected in these positive saliva samples was proportional to the real-time reverse-  
44 transcriptase PCR cycle threshold ( $C_T$ ), with SARS-CoV-2 RNA detected in as little as 05:43 ( $C_T$  21.08),  
45 07:59 ( $C_T$  24.47) and 08:35 ( $C_T$  25.27) minutes, respectively. The highest  $C_T$  where direct RT-LAMP  
46 detected SARS-CoV-2 RNA was 31.39 corresponding to a 1:40 dilution of a positive saliva sample with  
47 a starting  $C_T$  of 25.27. When RT-LAMP was performed on pools of SARS-CoV-2 negative saliva samples  
48 spiked with whole inactivated SARS-CoV-2 virus, RNA was detected at dilutions spanning 1:5 to 1:160  
49 representing  $C_T$ 's spanning 22.49-26.43. Here we describe a simple but critical rapid sample  
50 preparation method which can be used up front of RT-LAMP to permit direct detection of SARS-CoV-  
51 2 within saliva samples. Saliva is a sample which can be collected non-invasively without the use of  
52 highly skilled staff and critically can be obtained from both health care and home settings. Critically,  
53 this approach overcomes both the requirement and validation of different swabs and the global  
54 bottleneck observed in obtaining RNA extraction robots and reagents to enable molecular testing by  
55 PCR. Such testing opens the possibility of public health approaches for effective intervention to control  
56 the COVID-19 pandemic through regular SARS-CoV-2 testing at a population scale, combined with  
57 isolation and contact tracing for positive cases.

58

59

## 60 **Introduction**

61 The COVID-19 pandemic caused by the SARS-CoV-2 virus poses a profound global threat to  
62 communities, economic activity and healthcare systems. It is generally accepted that a safe and  
63 efficacious vaccine will not be widely available in the immediate future whilst uncertainty remains  
64 over the trajectory of the pandemic. Moreover, herd immunity from a high proportion of the  
65 population having become immune to SARS-CoV-2 is not thought to be a viable public health strategy  
66 by most observers. One public health approach that has been advocated for suppression of the COVID-  
67 19 pandemic is regular SARS-CoV-2 testing at a population scale, combined with isolation and contact  
68 tracing for positive cases<sup>1</sup>. Such an approach requires a rapid relatively inexpensive diagnostic test for  
69 the presence of the SARS-CoV-2 virus, ideally based on samples that can be simply collected in both  
70 health care and non-health care (e.g. home) settings<sup>2</sup>.

71

72 The current international gold standard for diagnosis of infection with SARS-CoV-2 is detection of viral  
73 RNA by real-time Reverse Transcriptase Polymerase Chain Reaction (rRT-PCR) from a naso-pharyngeal  
74 or oropharyngeal swab in viral transport medium<sup>3</sup>. However, the procedure for collecting a good  
75 quality sample using this approach requires a degree of training and skill, potentially exposes the  
76 sampler to infectious droplets, and can be uncomfortable and traumatic for the patient, especially if  
77 undertaken frequently. Critically, supply issues during the pandemic have led to bottlenecks in the  
78 availability of reagents for molecular assays, leading to demand for bespoke extraction kits far  
79 outweighing available supply and hampering testing efforts globally. Alongside this, the requirement  
80 for swab testing has led to key manufacturers being unable to cope with swab demand for patient  
81 sampling<sup>4,5</sup>. This has meant that laboratories have had to undertake frequent and time-consuming  
82 assay validation on different swab types. As such, exploring alternative sample types and RNA  
83 detection methods that circumvent the issues above is an attractive solution.

84

85 Saliva is a sample which shows promise for infection diagnostics, including for diagnostic detection of  
86 coronaviruses and has been shown as a site where SARS-CoV-2 is found in early infection<sup>6,7</sup>. Collection  
87 of saliva is straightforward and can be done by the patient themselves using a drooling technique, and  
88 collection devices include a simple, widely available, universal plastic container.

89  
90 Reverse-Transcription Loop-mediated isothermal AMPlification (RT-LAMP) is a highly sensitive  
91 reverse-transcription, autocycling, isothermal, strand displacement nucleic acid amplification  
92 technology<sup>8</sup> which is more resistant to inhibitors than rRT-PCR), enabling simplification and even  
93 removal of the extraction procedure<sup>9-11</sup>. LAMP technologies have been applied for the detection of a  
94 wide range of pathogens<sup>12-14</sup> including positive-sense RNA viruses<sup>10</sup> and has been used extensively in  
95 the veterinary<sup>15,16</sup> and plant industry<sup>17-19</sup> and more recently as a human diagnostic<sup>12,20,21</sup>. At the height  
96 of the SARS-CoV-2 epidemic in the UK in early 2020, Hampshire Hospitals NHS Foundation Trust (HHFT)  
97 validated a novel RT-LAMP assay for the detection of SARS-CoV-2 RNA within nasopharyngeal and  
98 oropharyngeal swabs either directly from swab, or following RNA extraction<sup>22</sup>. For direct detection of  
99 SARS-CoV-2 RNA from swab, a simple dilution of 1:20 of the viral transport media in nuclease free  
100 water (NFW) was shown to be sufficient to overcome inhibition and to achieve sensitivity (DSe) and  
101 specificity (DSp) of 67% and 97%, respectively. When setting rRT-PCR cycle threshold ( $C_T$ ) cut-offs of  
102  $\leq 33$  and  $\leq 25$ , the DSe increased to 75% and 100%, respectively, with the specificity retained. Within  
103 this first study<sup>22</sup>, preliminary evaluation of Direct RT-LAMP for detection of SARS-CoV-2 in other clinical  
104 samples was performed using fourteen saliva samples collected from hospital in-patients confirmed  
105 from paired swabs as positive and negative for SARS-CoV-2. Using a 1:20 dilution of saliva in NFW,  
106 SARS-CoV-2 RNA was detected as expected in four of the positive swab samples but was unexpectedly  
107 detected in only two of the saliva samples. This indicated that more work was required to optimize  
108 the crude sample preparation method for detection of SARS-CoV-2 in saliva. Herein we describe the  
109 further optimisation of a simple sample preparation method to permit direct detection of SARS-CoV-  
110 2 within saliva samples using Direct RT-LAMP.

111

## 112 **Materials and Methods**

### 113 ***Virus isolates and clinical specimens***

114

115 Optimisation of Direct RT-LAMP for detection of SARS-CoV-2 RNA in saliva was performed using three  
116 SARS-CoV-2 positive saliva samples collected from symptomatic patients at Hampshire Hospitals NHS  
117 Foundation Trust (HHFT) (n=1) and University Hospital Southampton (UHS) (n=2) who had previously  
118 had rRT-PCR positive SARS-CoV-2 positive naso-pharyngeal samples. An additional 15 SARS-CoV-2  
119 negative saliva samples collected from asymptomatic UHS healthcare staff were used to prepare a  
120 pooled sample for specificity analysis. For spiking experiments, one pool of 25 SARS-CoV-2 negative  
121 saliva samples from asymptomatic UHS staff, and a second pool of 5 SARS-CoV-2 negative saliva  
122 samples also from asymptomatic UHS staff, were used to prepare pooled samples for spiking with  
123 whole inactivated virus (SARS-CoV-2 at  $\sim 1 \times 10^5$  TCID<sub>50</sub>/ml was inactivated using beta-propiolactone  
124 (BPL). Collection of saliva involved the patient providing a fresh saliva sample into a 10ml universal  
125 container. Each positive saliva sample was diluted 1:1 in Mucolyse™ (active ingredient: dithiothreitol,  
126 Pro-Lab Diagnostics, UK) prior to dilution in either NFW or 10% Chelex® 100 Resin (Bio-Rad  
127 Laboratories, Watford, UK)<sup>23</sup>. Mucolyse™ was also added 1:1 to the final pool of negative saliva  
128 samples and the SARS-CoV-2 spiked pools.

129

### 130 ***RNA extraction***

131 The saliva sample collected within the HHFT was extracted using the Maxwell® RSC Viral Total Nucleic  
132 Acid Purification Kit (Promega UK Ltd., Southampton, UK) according to manufacturer's instructions.  
133 Briefly, 200 µl of sample was added to 223 µl of prepared lysis solution (including 5 µl per reaction of  
134 Genesig® Easy RNA Internal extraction control, Primerdesign Ltd, Chandler's Ford, UK). Samples were  
135 then inactivated for 10 minutes at room temperature within the safety cabinet and 10 minutes at 56°C  
136 on a heat block before automated RNA extraction using a Maxwell® RSC 48 Instrument (Promega UK  
137 Ltd., Southampton, UK). RNA was eluted in 50 µl of NFW.

138

139 The saliva samples collected from UHS were extracted using the MagMAX™CORE Nucleic acid  
140 purification kit (Thermofisher). Briefly, 10µl of sample (diluted in 190µl DEPC treated water) was  
141 added to 700µl of prepared lysis solution. Samples were then inactivated for 10 minutes at room  
142 temperature within the safety cabinet before automated RNA extraction using a KingfisherFlex  
143 (Thermofisher). RNA was eluted in 90 µl of NFW.

144

#### 145 ***Real-time reverse-transcription PCR (rRT-PCR)***

146 All rRT-PCR assays were performed in single replicates using 5 µl of RNA template. The saliva sample  
147 collected within the HHFT was analysed using the COVID-19 genesig® Real-Time PCR assay  
148 (Primerdesign Ltd, Chandler's Ford, UK) according to the manufacturer's guidelines, on a MIC qPCR  
149 Cycler (Bio Molecular Systems, London, UK). The cycling conditions were adjusted to the following: a  
150 reverse-transcription (RT) step of 10 minutes at 55°C, a hot-start step of 2 minutes at 95°C, and then  
151 45 cycles of 95°C for 10 seconds and 60°C for 30 seconds. The Genesig® COVID-19 positive control  
152 included in the kit, a negative extraction control, and a no template control were also included on  
153 each rRT-PCR run.

154

155 The saliva samples collected from the UHS and the spiked whole virus dilution series were tested using  
156 the E gene RT-PCR as described previously (Corman et al.,2020) using the AgPath-ID™ PCR kit  
157 (Thermofisher). Samples were run on an Aria qPCR Cycler (Agilent) and results analysed using the  
158 Agilent AriaMX 1.5 software. The cycling conditions were adjusted to the following: a reverse-  
159 transcription (RT) step of 10 minutes at 55°C, a hot-start step of 3 minutes at 94°C, and then 45 cycles  
160 of 94°C for 15 seconds and 60°C for 15-30 seconds during data acquisition. The SARS-CoV2 positive  
161 control RNA, a negative extraction control, and a no template control were also included on each rRT-  
162 PCR run.

163

164

165 ***Preparation of 10% (w/v) Chelex® 100 Resin***

166 10% (w/v) Chelex® 100 Resin was made up by resuspending Chelex® 100 Resin (200-400 mesh) (Bio-  
167 Rad Laboratories, catalogue number #142-1253) in Milli-Q® water at 10% (w/v). The solution was  
168 heated at 70°C for 30 minutes. Two washes in Milli-Q® water were performed by allowing the Chelex®  
169 100 Resin to settle, removing the supernatant, adding Milli-Q® water to 10% (w/v) and shaking. After  
170 a second wash, Milli-Q® water was added to give a final 10% Chelex® 100 (w/v) Resin solution.

171

172 ***Reverse-transcription loop-mediated isothermal amplification (RT-LAMP)***

173 RT-LAMP reactions were performed using OptiGene Ltd. (Camberley, UK) COVID-19\_Direct RT-LAMP  
174 KIT-500 kit which targets the *ORF1ab* region of the SARS-CoV-2 genome.

175

176 Each RT-LAMP reaction consisted of: 17.5 µl of RT-LAMP Isothermal Mastermix (containing 8 units of  
177 GspSSD2.0 DNA Polymerase, 7.5 units of Opti-RT reverse transcriptase and a proprietary fluorescent  
178 dsDNA intercalating dye and a proprietary enhancing enzyme), 2.5 µl of 10X COVID-19 Primer Mix,  
179 and 5 µl of RNA/sample. RT-LAMP reactions were performed in duplicate at 65°C for 20 mins on a  
180 Genie® HT (OptiGene Ltd., UK). An exponential increase in fluorescence ( $\Delta F$ ) indicated a positive  
181 reaction, which was quantified by a time to positivity ( $T_p$ ) value, called at the point where the  
182 fluorescence level on the amplification curve, crosses the threshold of 5000. To confirm the specificity  
183 of the amplification reaction, an anneal curve was performed: RT-LAMP products were heated to 98°C  
184 for 1 min, then cooled to 80°C decreasing the temperature by 0.05°C/s.

185

186 Genie® embedded software (OptiGene Ltd., UK) was utilised to analyse RT-LAMP results and define  
187 thresholds for result calling. All RT-LAMP reactions were performed in duplicate, and a sample was  
188 considered positive when a  $T_p$  was observed in at least one replicate with amplification above 5000

189 fluorescence points and had an anneal temperature of between 81.50°C and 84.05°C with a derivative  
190 above 2500 F/°C.

191

192 For Direct RT-LAMP, 5 µl of saliva diluted in NFW or 10% (w/v) Chelex® 100 Resin (Bio-rad) spanning 1  
193 in 5 to 1 in 640, with and without heat treatment (70°C for 4 minutes or 98°C for 2 mins) was added  
194 to the reaction. Heating was performed on a dry heat block. The same treatments were applied to the  
195 saliva pools spiked with whole inactivated virus and to the non-spiked negative saliva pool, however  
196 the first spiked saliva pool was only titrated as far as 1:40 in the first instance. After addition to direct  
197 RT-LAMP all treatments were pooled according to dilution (e.g. all temperature treatments were  
198 pooled according to the dilution) and extracted for rRT-PCR analysis.

199

## 200 **Results**

### 201 ***Optimisation of the Direct-RT-LAMP***

202 Optimization of the Direct RT-LAMP assay for detection of SARS-CoV-2 was determined using three  
203 positive saliva samples, a pool of non-spiked negative saliva and a pool of spiked saliva.

204 The three positive saliva samples diluted 1:1 in Mucolyse™ rRT-PCR C<sub>T</sub> values were 21.08, 24.47 and  
205 25.27 (Table 1). For the first spiked saliva pool, the whole inactivated virus spiked into saliva prior to

206 dilution rRT-PCR  $C_T$  was 26.70 (Table 2). For the second spiked saliva pool, the whole inactivated virus  
207 spiked into saliva diluted 1:1 in Mucolyse™ (prior to further dilutions) rRT-PCR  $C_T$  was 22.86 (Table 3).

208

209 From rRT-PCR data samples were assessed for sensitivity using the Direct-LAMP protocol. Samples  
210 were assessed in order of highest viral load by rRT-PCR ( $C_T$  21.08: Table 1, Panel A) result to lowest ( $C_T$   
211 25.27: Table 1, Panel C).

212

213 The saliva sample with the highest viral load ( $C_T$  21.08) when diluted in water was detected in  
214 duplicate in five dilutions (1:40 to 1:640) without heat treatment, in all eight dilutions (1:5 to 1:640)  
215 following 70°C for 4 mins and in seven dilutions 1 in 5 to 1 in 640 following 98°C for 2 mins (Table 1,  
216 Panel A). When diluted in 10% (w/v) Chelex® 100 Resin the same saliva sample ( $C_T$  21.08) was detected  
217 in duplicate in seven dilutions (1:10 to 1:640) without heat treatment and in all eight dilutions (1:5 to  
218 1:640) following either 70°C for 4 minutes or 98°C for 2 minutes (Table 1, Panel A).

219

220 The saliva sample with a  $C_T$  of 24.47 when diluted in water was not detected in duplicate in any dilution  
221 without heat or following 70°C for 4 mins (Table 1, Panel B). This sample was detected in duplicate in  
222 three dilutions (1:5 to 1 in 20) only following 98°C for 2 mins (table 1). When diluted in 10% (w/v)  
223 Chelex® 100 Resin the same saliva sample ( $C_T$  24.47) was detected in duplicate in one dilution (1:20)  
224 without heat treatment, in 4 dilutions (1:10 to 1:80) following 70°C for 4 minutes and in five dilutions  
225 (1:5 to 1:40 and 1: 160) following 98°C for 2 minutes (Table 1, Panel B).

226

227 The saliva sample with the lowest viral load ( $C_T$  25.27) when diluted in water was not detected in  
228 duplicate in any dilution without heat or following 70°C for 4 mins (Table 1, Panel C). This sample was  
229 detected in duplicate in one dilution (1:5) only following 98°C for 4 mins (Table 1, Panel C). When  
230 diluted in 10% (w/v) Chelex® 100 Resin the same saliva sample ( $C_T$  25.27) was detected in duplicate in

231 two dilutions (1:40 and 1:80) without heat treatment, in no dilutions following 70°C for 4 minutes and  
232 in four dilutions (1:5 to 1:40) following 98°C for 2 minutes (Table 1, Panel C).

233  
234 The pool of saliva samples negative for SARS-CoV-2 was negative also on Direct RT-LAMP for all assay  
235 conditions (data not shown as all samples reported a negative result).

236  
237 The whole inactivate virus spiked into saliva with a  $C_T$  of 26.70 when diluted in water was detected in  
238 duplicate at one dilution (1:40) without heat, in three dilutions (1:10, 1:20, 1:40) following 70°C for 4  
239 mins and in two dilutions (1:5 and 1:10) following 98°C for 2 mins (Table 2). When diluted in 10% (w/v)  
240 Chelex® 100 Resin the same saliva sample was detected in duplicate in two dilutions (1:20 and 1:40)  
241 without heat treatment, in three dilutions (1:10, 1:20, 1:40) following 70°C for 4 minutes and in all  
242 four dilutions (1:5 to 1:40) following 98°C for 2 minutes (Table 2).

243  
244 A further dilution series of SARS-CoV-2 inactivated whole virus was prepared to include the 1:1  
245 Mucolyse™ dilution that is used for clinical samples and to extend beyond a 1:40 dilution to reach the  
246 limit of detection of the Direct RT-LAMP assay. The whole inactivated virus spiked into saliva ( $C_T$  of  
247 22.86 when diluted in water was detected in duplicate at one dilution (1:80) without heat, in three  
248 dilutions (1:5, 1:10 and 1:80) following 70°C for 4 mins and in three dilutions (1:5, 1:10 and 1:40)  
249 following 98°C for 2 mins (Table 3). When diluted in 10% (w/v) Chelex® 100 Resin the same saliva  
250 sample was detected in duplicate in three dilutions (1:20, 1:40 and 1:80) without heat treatment, in  
251 six dilutions (1:5, 1:10, 1:20, 1:40, 1:80 and 1:160) following 70°C for 4 minutes and in six dilutions  
252 (1:5, 1:10, 1:20, 1:40, 1:80, 1:160) following 98°C for 2 minutes (Table 3).

253  
254 **Discussion**

255 This study describes the rapid optimization of a method to permit direct detection of SARS-CoV-2 RNA  
256 within saliva samples using RT-LAMP, without need for prior RNA extraction. Our previous publication

257 was focused on optimizing conditions for rapid detection of SARS-CoV-2 within viral transport media  
258 from swabs samples<sup>22</sup>. In that publication, preliminary evaluation of the direct transfer of the swab  
259 sample preparation method for comparable detection in paired saliva samples was poor, indicating  
260 that a different sample preparation method would be required for optimal detection of SARS-CoV-2  
261 RNA in crude saliva. In this study we show for the first time that the optimal sample preparation  
262 method to allow SARS-CoV-2 RNA detection within crude saliva samples (1:1 mix of saliva and  
263 Mucolyse™ (active ingredient dithiothreitol)) requires saliva dilution in 10% (w/v) Chelex® 100 Resin  
264 and heating to 98°C 2 minutes prior to adding to the direct RT-LAMP reagents.

265

266 When using this approach SARS-CoV-2 RNA was reliably detected in duplicates for a wide range of  
267 dilutions assessed from positive saliva samples with a starting C<sub>T</sub> value of 21.08, 24.47 and 25.27. The  
268 combination of a chelating resin (Chelex® 100 Resin) and heating the sample to 98°C successfully  
269 overcame matrix inhibition and or matrix “protection” of viral capsid nucleic acid release which was  
270 observed in the samples which did not receive this protocol. The time to positivity (speed at which  
271 SARS-CoV-2 RNA was detected in saliva) was proportional to the “strength” of the saliva sample after  
272 addition of 1:1 Mucolyse™ (active ingredient: dithiothreitol) as determined by real-time reverse-  
273 transcriptase PCR with SARS-CoV-2 detected in 05:55 (C<sub>T</sub> 21.08), 08:39 (C<sub>T</sub> 24.47) and 09:15 (C<sub>T</sub> 25.27)  
274 minutes, respectively when using a dilution of 1:10 of saliva into 10% (w/v) Chelex® 100 Resin.  
275 Importantly, using this method, no amplification was detected in the negative pooled saliva samples,  
276 confirming the compatibility of this sample preparation approach in maintaining specificity of the  
277 assay.

278

279 Due to the lower prevalence of SARS-CoV-2 at the time of optimisation of this sample preparation  
280 method, only three positive saliva samples were available for analysis. To strengthen conclusions  
281 drawn from these clinical specimens spiked dilution series of whole inactivated virus spiked into  
282 pooled saliva were also evaluated with equivalent results obtained. This method should therefore be

283 translatable to saliva samples regardless of whether they are obtained from symptomatic or  
284 asymptomatic patients.

285

286 Studies in macaque monkeys demonstrated that the salivary glands in the mouth are the first site in  
287 the body to be affected by SARS-CoV infection<sup>24</sup> and several groups have reported high sensitivity and  
288 specificity saliva of rRT-PCR for SARS-CoV-2 in COVID-19 patients<sup>25,26</sup>. SARS-CoV-2 is therefore present  
289 in saliva samples early in the course of infection and can be spread to other individuals efficiently  
290 through salivary droplets generated when talking loudly or singing<sup>27</sup>. Population screening of saliva  
291 samples may therefore be an effective strategy to detect the important group of people who are  
292 infectious but not yet symptomatic. There is also evidence that SARS-CoV-2 may be present in saliva  
293 during the recovery phase from infection after upper respiratory samples have become negative<sup>28</sup>,  
294 making saliva an attractive sample type for identification of individuals in the population who could  
295 transmit infection<sup>4</sup>.

296

297 These findings add to the increasing literature supporting saliva as a reliable sample type in which to  
298 detect SARS-Cov-2 RNA. Using saliva samples collected in a simple collection pot, we described an  
299 approach that paves the way for a rapid diagnostic test for the presence of the SARS-CoV-2 virus based  
300 on samples that can simply be collected at home or in other non-health care settings. Critically, this  
301 approach overcomes both the requirement and validation of different swabs and the global  
302 bottleneck observed in obtaining RNA extraction robots and reagents to enable molecular testing by  
303 PCR. Such testing opens the possibility of public health approaches for suppression of the COVID-19  
304 pandemic through regular SARS-CoV-2 testing at a population scale at relatively low cost, combined  
305 with isolation and contact tracing for positive cases.

306

307

308 **Ethics**

309 UHS saliva collection and analysis was conducted with informed written consent following institutional  
310 review board approval (ENACT – Enabling New Approaches for CoVID-19 Treatment).

311

### 312 **Funding**

313 This work was funded by a Department of Health and Social Care award to the University of  
314 Southampton (Grant Reference Number 2020/032 (Feasibility study for city-wide testing using saliva  
315 based LAMP testing)). The views expressed are those of the authors and not necessarily those of the  
316 Department of Health and Social Care. KMG is supported by the UK Medical Research Council  
317 (MC\_UU\_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-  
318 10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)) and the British  
319 Heart Foundation (RG/15/17/3174). For this project, Emma Howson was on secondment at GeneSys  
320 Biotech Ltd, which was part funded by The Pirbright Institute Flexible Talent Mobility Account (FTMA)  
321 under BBSRC grant BB/S507945/1. The analytical testing was conducted at HHFT and at Defra  
322 maintained facilities at the Animal and Plant Health Agency-Weybridge.

323

324 **References**

- 325 1 Peto Julian, Alwan Nisreen A., Godfrey Keith M., Burgess Rochelle A., Hunter David J., Riboli  
326 Elio, et al. Universal weekly testing as the UK COVID-19 lockdown exit strategy. *Lancet*  
327 2020;**395**(10234):1420–1. Doi: 10.1016/S0140-6736(20)30936-3.
- 328 2 PE Sax. Rapid-inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-  
329 vaccine. Available at [https://blogs.jwatch.org/hiv-id-observations/index.php/rapid-](https://blogs.jwatch.org/hiv-id-observations/index.php/rapid-inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-vaccine/2020/07/05/)  
330 [inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-](https://blogs.jwatch.org/hiv-id-observations/index.php/rapid-inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-vaccine/2020/07/05/)  
331 [vaccine/2020/07/05/](https://blogs.jwatch.org/hiv-id-observations/index.php/rapid-inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-vaccine/2020/07/05/) n.d.
- 332 3 World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in  
333 suspected human cases. Available at [https://www.who.int/publications/i/item/laboratory-](https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)  
334 [testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117](https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117) n.d.
- 335 4 Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic  
336 accuracy study 2020;(January).
- 337 5 Reuters. UK has fixed swab shortage problem for coronavirus testing. Available at  
338 [https://uk.reuters.com/article/uk-health-coronavirus-britain-swabs/uk-has-fixed-swab-](https://uk.reuters.com/article/uk-health-coronavirus-britain-swabs/uk-has-fixed-swab-shortage-problem-for-coronavirus-testing-minister-idUKKBN21K2SA)  
339 [shortage-problem-for-coronavirus-testing-minister-idUKKBN21K2SA](https://uk.reuters.com/article/uk-health-coronavirus-britain-swabs/uk-has-fixed-swab-shortage-problem-for-coronavirus-testing-minister-idUKKBN21K2SA) n.d.
- 340 6 Wei Shan, Kohl Esther, Djandji Alexandre, Morgan Stephanie, Whittier Susan, Mansukhani  
341 Mahesh, et al. Field-deployable, rapid diagnostic testing of saliva samples for SARS-CoV-2.  
342 *MedRxiv* 2020:2020.06.13.20129841. Doi: 10.1101/2020.06.13.20129841.
- 343 7 Sri Santosh Tatikonda, Parmar Reshu, Anand Hanish, Srikanth Konkati, Saritha Madham. A  
344 Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19. *Cureus*  
345 2020;**12**(4). Doi: 10.7759/cureus.7708.
- 346 8 Tsugunori Notomi, Okayama Hiroto, Masubuchi Harumi, Yonekawa Toshihiro, Watanabe  
347 Keiko, Amino Nobuyuki, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids*  
348 *Res* 2000;**28**(12):63.
- 349 9 Keikha Masoud. *LAMP Method as One of the Best Candidates for Replacing with PCR Method.*

- 350 vol. 25. n.d.
- 351 10 Howson E. L. A., Armson B., Lyons N. A., Chepkwony E., Kasanga C. J., Kandusi S., et al. Direct  
352 detection and characterization of foot-and-mouth disease virus in East Africa using a field-  
353 ready real-time PCR platform. *Transbound Emerg Dis* 2018;**65**(1):221–31. Doi:  
354 10.1111/tbed.12684.
- 355 11 Tsai Chi Chu, Shih Huei Chuan, Ko Ya Zhu, Wang Ren Huang, Li Shu Ju, Chiang Yu Chung. Direct  
356 LAMP assay without prior DNA purification for sex determination of papaya. *Int J Mol Sci*  
357 2016;**17**(10). Doi: 10.3390/ijms17101630.
- 358 12 Mahony James, Chong Sylvia, Bulir David, Ruyter Alexandra, Mwawasi Ken, Waltho Daniel.  
359 Multiplex loop-mediated isothermal amplification (M-LAMP) assay for the detection of  
360 influenza A/H1, A/H3 and influenza B can provide a specimen-to-result diagnosis in 40min with  
361 single genome copy sensitivity. *J Clin Virol* 2013;**58**(1):127–31. Doi:  
362 <https://doi.org/10.1016/j.jcv.2013.06.006>.
- 363 13 Wong Y. P., Othman S., Lau Y. L., Radu S., Chee H. Y. Loop-mediated isothermal amplification  
364 (LAMP): a versatile technique for detection of micro-organisms. *J Appl Microbiol* 2018:626–43.  
365 Doi: 10.1111/jam.13647.
- 366 14 Zhao Jiangtao, Feng Ruo. Sensitive and rapid detection of Zika virus by loop-mediated  
367 isothermal amplification. *Virus Genes* 2019;**55**(1):43–50. Doi: 10.1007/s11262-018-1612-x.
- 368 15 Fowler Veronica L., Howson Emma L.A., Madi Mikidache, Mioulet Valérie, Caiusi Chiara,  
369 Pauszek Steven J., et al. Development of a reverse transcription loop-mediated isothermal  
370 amplification assay for the detection of vesicular stomatitis New Jersey virus: Use of rapid  
371 molecular assays to differentiate between vesicular disease viruses. *J Virol Methods*  
372 2016;**234**:123–31. Doi: 10.1016/j.jviromet.2016.04.012.
- 373 16 Armson Bryony, Walsh Charlotte, Morant Nick, Fowler Veronica L, Knowles Nick J., Clark  
374 Duncan. The development of two field-ready reverse transcription loop-mediated isothermal  
375 amplification assays for the rapid detection of Seneca Valley virus 1. *Transbound Emerg Dis*

- 376 2019;**66**(1):497–504. Doi: 10.1111/tbed.13051.
- 377 17 Feng Wenzhuo, Nukaya Akira, Satou Mamoru, Fukuta Naoko, Ishiguro Yasushi, Suga Haruhisa,  
378 et al. Use of LAMP detection to identify potential contamination sources of plant-pathogenic  
379 pythium species in hydroponic culture systems of tomato and eustoma. *Plant Dis*  
380 2018;**102**(7):1357–64. Doi: 10.1094/PDIS-10-17-1679-RE.
- 381 18 Feng Wenzhuo, Hieno Ayaka, Kusunoki Mikio, Suga Haruhisa, Kageyama Koji. LAMP detection  
382 of four plant-pathogenic oomycetes and its application in lettuce fields. *Plant Dis*  
383 2019;**103**(2):298–307. Doi: 10.1094/PDIS-05-18-0858-RE.
- 384 19 Tomlinson Jenny, Boonham Neil. Real-Time LAMP for *Chalara fraxinea* Diagnosis. *Methods Mol*  
385 *Biol* 2015;**1302**:75–83. Doi: 10.1007/978-1-4939-2620-6\_6.
- 386 20 Yan Chao, Cui Jinghua, Huang Lei, Du Bing, Chen Lu, Xue Guanhua, et al. Rapid and visual  
387 detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated  
388 isothermal amplification assay. *Clin Microbiol Infect* 2020. Doi: 10.1016/j.cmi.2020.04.001.
- 389 21 de Paz Héctor David, Brotons Pedro, Esteva Cristina, Muñoz-Almagro Carmen. Validation of a  
390 Loop-Mediated Isothermal Amplification Assay for Rapid Diagnosis of Invasive Pneumococcal  
391 Disease. *Front Cell Infect Microbiol* 2020;**10**. Doi: 10.3389/fcimb.2020.00115.
- 392 22 Fowler Veronica L, Armson Bryony, Gonzales Jose L, Wise Emma L, Howson Emma L A, Vincent-  
393 Mistiaen Zoe, et al. A reverse-transcription loop-mediated isothermal amplification (RT-LAMP)  
394 assay for the rapid detection of SARS-CoV-2 within nasopharyngeal and oropharyngeal swabs  
395 at Hampshire Hospitals NHS Foundation Trust Keywords. *MedRxiv* 2020:2020.06.30.20142935.  
396 Doi: 10.1101/2020.06.30.20142935.
- 397 23 Walsh P. Sean, Metzger David A., Higuchi Russell. Biotechniques 30th anniversary gem Chelex  
398 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material.  
399 *Biotechniques* 2013;**54**(3):506–13.
- 400 24 Liu L., Wei Q., Alvarez X., Wang H., Du Y., Zhu H., et al. Epithelial Cells Lining Salivary Gland  
401 Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the

- 402 Upper Respiratory Tracts of Rhesus Macaques. *J Virol* 2011;**85**(8):4025–30. Doi:  
403 10.1128/jvi.02292-10.
- 404 25 Zhu Jialou, Guo Jiubiao, Xu Yuzhong, Chen Xinchun. Viral dynamics of SARS-CoV-2 in saliva from  
405 infected patients. *J Infect* 2020;(xxxx):10–2. Doi: 10.1016/j.jinf.2020.06.059.
- 406 26 Azzi Lorenzo, Carcano Giulio, Gianfagna Francesco, Grossi Paolo, Dalla Daniela, Genoni Angelo,  
407 et al. Saliva is a reliable tool to detect SARS-CoV-2 2020;(January).
- 408 27 Han Pingping. Saliva — Friend and Foe in the COVID-19 Outbreak 2020.
- 409 28 Azzi Lorenzo, Carcano Giulio, Dalla Gasperina Daniela, Sessa Fausto, Maurino Vittorio, Baj  
410 Andreina. Two cases of COVID-19 with positive salivary and negative pharyngeal or respiratory  
411 swabs at hospital discharge: a rising concern. *Oral Dis* 2020;(April):1–3. Doi:  
412 10.1111/odi.13368.
- 413

**Table 1.** Sample preparation optimisation for direct detection of SARS-CoV-2 in crude saliva

Treatment	Panel A: AHHFT Saliva C <sub>T</sub> 21.08 (1:1 in Mucolyse™)								Panel B: UHS Saliva C <sub>T</sub> 24.47 (1:1 in Mucolyse™)						Panel C: UHS Saliva C <sub>T</sub> 25.27 (1:1 in Mucolyse™)								
	Dilution	rRT-PCR		No Heat		70°C 4 mins		98°C 2 mins		rRT-PCR C <sub>T</sub>	No Heat		70°C 4 mins		98°C 2 mins		rRT-PCR C <sub>T</sub>	No Heat		70°C 4 mins		98°C 2 mins	
		C <sub>T</sub>	Tp	Anneal	Tp	Anneal	Tp	Anneal	Tp		Anneal	Tp	Anneal	Tp	Anneal	Tp		Anneal	Tp	Anneal	Tp	Anneal	Tp
Saliva in NFW	1 in 5	19.92			08:32	83.38	06:53	83.66	25.83					13:21	83.39	26.39			12:14	83.05			
	1 in 5				08:15	83.32	06:59	83.68						13:25	83.24				10:26	83.17			
	1 in 10	19.25			08:07	83.30	07:05	83.53	26.34					14:38	83.11	27.97							
	1 in 10				07:35	83.40	06:56	83.55						13:06	83.41				11:48	83.13			
	1 in 20	19.75	12:28	83.56	07:50	83.33	07:20	83.47	26.21	12:09	83.65			10:00	83.29	28.98							
	1 in 20				08:08	83.39	07:37	83.52						09:38	83.34								
	1 in 40	20.41	09:16	83.65	08:45	83.37	07:32	83.65	27.24					13:46	83.25	30.36		14:29	83.81				
	1 in 40		10:40	83.59	08:54	83.29	07:34	83.54															
	1 in 80	21.32	09:08	83.75	08:43	84.02	08:18	83.69	28.15							31.22							
	1 in 80		09:27	83.71	08:25	83.94	07:57	83.60										11:42	83.08				
	1 in 160	22.66	08:21	83.70	10:15	83.95	08:10	83.62	30.09							32.17							
	1 in 160		08:25	83.62	10:57	84.00	09:47	83.59															
1 in 320	23.58	08:30	83.63	09:21	83.71	10:07	83.60	30.95							33.86	12:17	83.09						
1 in 320		09:19	83.66	08:41	83.73	09:36	83.67																
1 in 640	23.99	09:42	83.66	08:54	83.01			31.83							34.70								
1 in 640		08:28	83.66	08:38	83.97	08:25	83.68																
Saliva in 10% (w/v) Chelex® Resin	1 in 5	18.84			06:05	83.69	05:43	83.73	25.97					08:31	83.83	28.23			09:18	83.39			
	1 in 5		14:32	83.50	06:09	83.67	05:47	83.68					10:17	83.40	12:16		83.60			08:35	83.35		
	1 in 10	19.22	08:51	83.58	06:07	83.54	05:54	83.70	26.34			09:24	83.30	09:02	83.36	29.96			09:37	83.32			
	1 in 10		09:47	83.56	06:07	83.56	05:56	83.65		11:21	83.27	09:32	83.31	08:17	83.31		09:29	83.13	10:22	83.22	08:53	83.32	
	1 in 20	19.7	07:44	83.52	06:15	83.43	06:03	83.61	27.02	12:45	83.19	08:30	83.31	08:20	83.23	30.17			09:20	83.19			
	1 in 20		08:38	83.55	06:11	83.62	06:05	83.72		12:57	83.28	09:49	83.40	08:29	83.35				13:10	83.06	10:36	83.16	
	1 in 40	21.08	08:14	83.61	06:18	83.62	06:07	83.68	28.27			12:57	83.52	07:59	83.33	31.39	12:19	83.05			09:44	83.15	
	1 in 40		07:37	83.52	06:18	83.56	06:13	83.67				08:46	83.32	14:06	83.32		12:52	83.05	08:48	83.12	10:20	83.96	
	1 in 80	22.25	07:37	83.87	06:29	83.82	06:32	83.62	28.47			11:51	83.32	10:50	83.35	32.43	11:19	83.05					
	1 in 80		07:38	83.03	06:31	83.75	06:37	83.60				10:25	83.31				09:25	83.26	08:11	83.44			
	1 in 160	23.05	07:47	83.56	06:57	83.74	06:51	83.61	29.52					10:41	83.41	33.88							
	1 in 160		07:32	83.53	06:47	83.65	06:52	83.59				13:10	83.15	09:46	83.41								
1 in 320	24.05	08:00	83.58	07:02	83.68	07:08	83.60	30.26					13:22	83.28	34.98								
1 in 320		08:03	83.58	07:27	83.68	07:15	83.60																
1 in 640	24.6	08:12	83.61	07:25	83.66	07:32	83.65	31.55							34.98								
1 in 640		08:33	83.60	08:04	83.58	07:22	83.63						12:10	83.23									

HHFT: Hampshire Hospitals NHS Foundation Trust; UHS: University Hospital Southampton; NFW: Nuclease free water; C<sub>T</sub>: Cycle Threshold; Tp: Time to positivity. Dark grey shading indicates samples positive in duplicates by direct RT-LAMP, Light grey shading indicates samples positive in single replicates. Blank wells represent no amplification detected (negative) in Direct RT-LAMP. For Tp 00:00 represents minutes:seconds.

**Table 2:** Dilution series of inactivated whole virus spiked into pooled saliva from 25 negative patient samples (no predilution 1:1 in Mucolyse™)

Treatment	Dilution	No Heat			70°C 4 mins			98°C 2 mins		
		rRT-PCR C <sub>T</sub>	Tp	Anneal	rRT-PCR C <sub>T</sub>	Tp	Anneal	rRT-PCR C <sub>T</sub>	Tp	Anneal
Saliva in NFW	1 in5	24.19			21.37			22.04	09:40	83.53
	1 in5					11:57	83.25		12:37	83.33
	1 in 10	20.39			22.23	10:09	83.34	22.25	11:03	83.77
	1 in 10		12:23	83.11		09:58	83.34		11:39	83.22
	1 in 20	21.21			23.21	09:24	83.30	23.07	11:16	83.33
	1 in 20		12:55	83.16		09:53	83.35			
1 in 40	22.64			24.62	11:54	83.4	24.83	14:29	83.15	
1 in 40		10:02	83.33		09:16	83.45				
Saliva in 10% (w/v) Chelex® 100 Resin	1 in5	23.71			21.48			22.96	08:07	83.57
	1 in5					11:02	83.32		07:51	83.48
	1 in 10	19.78			22.95	09:04	83.37	20.8	08:17	83.46
	1 in 10		12:01	83.24		09:17	83.33		07:35	83.38
	1 in 20	21.08			23.22	10:55	83.28	23.09	07:54	83.35
	1 in 20		10:20	83.24		08:35	83.35		08:13	83.39
1 in 40	21.85			23.92	09:21	83.3	23.89	08:48	83.62	
1 in 40		09:16	83.32		10:08	83.27		08:04	83.54	

NFW: Nuclease free water; C<sub>T</sub>: Cycle Threshold; Tp: Time to positivity. Dark grey shading indicates samples positive in duplicates by direct RT-LAMP, Light grey shading indicates samples positive in single replicates. Blank wells represent no amplification detected (negative) in Direct RT-LAMP. For Tp 00:00 represents minutes:seconds.

**Table 3:** Dilution series of inactivated whole virus spiked into pooled saliva from five negative patient samples (predilution 1:1 in Mucolyse™)

Treatment	Dilution	No Heat (spiked sample 1:1 in Mucolyse™)			70°C 4 mins (spiked sample 1:1 in Mucolyse™)			98°C 2 mins (spiked sample 1:1 in Mucolyse™)		
		rRT-PCR C <sub>T</sub>	Tp	Anneal	rRT-PCR C <sub>T</sub>	Tp	Anneal	rRT-PCR C <sub>T</sub>	Tp	Anneal
Saliva in NFW	1 in 5	21.97			21.97	11:31	83.63	21.97	09:01	83.41
	1 in 5					10:30	83.48		09:34	83.39
	1 in 10	22.32			22.32	13:36	83.42	22.32	09:37	83.36
	1 in 10					10:11	83.39		11:31	83.29
	1 in 20	23.67			23.67	10:14	83.20	23.67	11:52	83.23
	1 in 20									
	1 in 40	24.32			24.32	10:15	83.60	24.32	08:44	83.44
	1 in 40		12:38	83.37					10:38	83.40
	1 in 80	25.3	09:55	83.58	25.3	09:30	83.35	25.3	14:58	83.37
	1 in 80		09:06	83.44		09:42	83.35			
	1 in 160	26.81			26.81			26.81	14:05	83.32
	1 in 160									
1 in 320	28.77			28.77			28.77			
1 in 320										
1 in 640	29.72	10:10	83.63	29.72			29.72			
1 in 640										
1 in 1280	29.85			29.85			29.85			
1 in 1280										
Saliva in 10% (w/v) Chelex® 100 Resin	1 in 5	22.49			22.49	07:21	83.68	22.49	07:11	83.50
	1 in 5					07:34	83.54		07:43	83.41
	1 in 10	23.17			23.17	07:48	83.58	23.17	10:06	83.40
	1 in 10					08:16	83.45		08:32	83.35
	1 in 20	24.33	10:11	83.58	24.33	07:41	83.43	24.33	08:42	83.35
	1 in 20		10:20	83.59		07:41	83.46		08:39	83.40
	1 in 40	25.5	12:30	83.53	25.5	08:05	83.45	25.5	08:38	83.41
	1 in 40		11:52	83.38		08:07	83.28		07:55	83.32
	1 in 80	26.63	07:59	83.67	26.63	10:42	83.52	26.63	10:47	83.32
	1 in 80		09:34	83.56		09:05	83.41		10:45	83.24
	1 in 160	26.43	11:14	83.54	26.43	10:00	83.48	26.43	10:22	83.23
	1 in 160					09:50	83.40		10:26	83.22
1 in 320	27.31			27.31	09:35	83.55	27.31			
1 in 320										
1 in 640	28.56			28.56	09:00	83.59	28.56	09:35	83.37	
1 in 640										
1 in 1280	29.26			29.26			29.26			
1 in 1280										

NFW: Nuclease free water; C<sub>T</sub>: Cycle Threshold; Tp: Time to positivity. Dark grey shading indicates samples positive in duplicates by direct RT-LAMP, Light grey shading indicates samples positive in single replicates.

Blank wells represent no amplification detected (negative) in Direct RT-LAMP. For Tp 00:00 represents minutes:seconds.